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ABSTRACT
Objectives: This study is a process evaluation of the
Quality Improvement in Chronic Kidney Disease
(QICKD) study, comparing audit-based education (ABE)
and sending clinical guidelines and prompts (G&P)
with usual practice, in improving systolic blood
pressure control in primary care. This evaluation aimed
to explore how far clinical staff in participating
practices were aware of the intervention, and why
change in practice might have taken place.
Setting: 4 primary care practices in England: 2
received ABE, and 2 G&P. We purposively selected 1
northern/southern/city and rural practice from each
study arm (from a larger pool of 132 practices as part
of the QICKD trial).
Participants: The 4 study practices were purposively
sampled, and focus groups conducted with staff from
each. All staff members were invited to attend.
Interventions: Focus groups in each of 4 practices, at
the mid-study point and at the end. 4 additional trial
practices not originally selected for in-depth process
evaluation took part in end of trial focus groups, to a
total of 12 focus groups. These were recorded,
transcribed and analysed using the framework
approach.
Results: 5 themes emerged: (1) involvement in the
study made participants more positive about the CKD
register; (2) clinicians did not always explain to
patients that they had CKD; (3) while practitioners
improved their monitoring of CKD, many were sceptical
that it improved care and were more motivated by pay-
for-performance measures; (4) the impact of study
interventions on practice was generally positive,
particularly the interaction with specialists, included in
ABE; (5) the study stimulated ideas for future clinical
practice.
Conclusions: Improving quality in CKD is complex.
Lack of awareness of clinical guidelines and scepticism
about their validity are barriers to change. While pay-
for-performance incentives are the main driver for
change, quality improvement interventions can have a
complementary influence.
BACKGROUND
Chronic kidney disease (CKD) is a common
condition and an increasingly important
public health issue.1 It is estimated that CKD
amounts to approximately 1.3% of annual
health service spending in England.2 CKD is
an established, independent risk factor for
cardiovascular disease;3 signiﬁcantly more
patients with CKD die from cardiovascular
complications than progress to end-stage
kidney disease.4 5 Most patients with
mild-to-moderate CKD are treated in primary
care.6 General practice is therefore an
important service sector to target for initia-
tives to improve CKD care, principally by low-
ering blood pressure (BP), and to slow
progression of renal disease7 and reduce car-
diovascular risk.8 9
There is limited evidence about how best
to improve the quality of CKD management
in primary care.10 The Quality Improvement
in Chronic Kidney Disease (QICKD) study
was designed to address this question.
Strengths and limitations of this study
▪ This study provides important analysis of qualitative
factors that affect chronic kidney disease manage-
ment in primary care, beyond pay-for-performance
strategies.
▪ Involvement in the study was rewarding, made
participants more positive about CKD, and they
perceived improve care.
▪ Many were sceptical that identifying CKD
improved care and pay-for-performance was a
greater motivator.
▪ The study assessed a small number of practices
(four in each arm, eight in total), and results
may have been strongly influenced by opinion
leaders within practices.
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QICKD was a three-arm cluster randomised control
study comparing the effect of two recognised quality
improvement (QI) interventions with usual practice
(UP) in improving systolic BP control in CKD, in
primary care settings across England.11 The two QI inter-
ventions were audit-based education (ABE) and guide-
lines and prompts (G&P). ABE is a QI intervention
developed over the past 15 years, which provides educa-
tion, peer support, and uses audit to document the gap
between achievement and guidelines. This is a complex,
non-judgemental, educational intervention underpinned
by the use of IT to extract and make comparisons
between practices and against evidence-based guidelines
(box1).12 In observational studies, ABE improved the
quality of cardiovascular disease (including CKD) man-
agement,13 as well as in the QICKD trial.14 G&P is a
much less elaborate intervention and the most com-
monly used QI intervention in primary care.15 This
usually involves distribution of clinical guidelines, gener-
ally on paper, sometimes with postal reminders as well as
internet resources.
The QICKD trial reported a modest but statistically sig-
niﬁcant improvement in systolic BP in people with CKD
exposed to ABE compared with UP (OR of 1.24 of
achieving at least a 5 mm Hg reduction in systolic BP),
whereas G&P showed no signiﬁcant difference.14
Given the complex nature of QI interventions such as
G&P and ABE, we carried out a process evaluation to
explore practitioners’ perceptions of the extent to which
they were exposed to the intervention, the nature of that
exposure and the degree to which the trial interventions
might have inﬂuenced practice. A secondary aim of the
study was to identify what factors might have inﬂuenced
the management of CKD in community settings over the
course of the trial.
During the course of the trial, there were a number of
changes in primary care that affected CKD manage-
ment. Pay-for-performance (P4P) was introduced in
April 2004, mainly targeted on vascular disease, with a
CKD domain added in 2006. This scheme uses routine
data to determine the level of case ascertainment, on a
disease register, and sets ﬁnancially incentivised quality
indicators; practitioners are asked to maintain a list of
patients reaching the criteria for a diagnosis of CKD and
ensure that they meet certain treatment targets. The
CKD indicator includes a treatment target of keeping
BP below 140/85 mm Hg preferentially using
angiotensin-modulating drugs in the presence of pro-
teinuria. However, national evidence-based guidance
proposes different thresholds and targets for treatment.
P4P guidance sets less challenging BP levels than
national evidence-based guidelines (table 1).
METHODS
Overview: We identiﬁed four practices, two from each
active study arm for in-depth process evaluation. These
practices undertook two focus groups: one at the mid-
point during the study and another at the end of the
study. In addition, another four practices undertook a
focus group at the end of the study. The focus groups
were recorded, transcribed and analysed using the
framework approach.16
Description of the QICKD trial practices
We recruited 132 practices, with 16 dropping out before
randomisation. There were 30, 32 and 31 practices allo-
cated to the ABE, G&P and UP arms, respectively. In
addition, we recruited a further 10 per arm who also
received a questionnaire about their conﬁdence and
competence in managing CKD (but due to an allocation
Box 1 Components of audit-based education (ABE)
ABE is an intervention developed over 10 years ago; its aim is to
provide feedback about performance against guidance. ABE
includes feedback about quality compared with peers in a work-
shop setting usually led by a local general practitioner (GP) with a
specialist (nephrology consultant or nurse) available as an expert
resource, and also supported by academic detailing. Usually, ABE
also identified lists of patients within the practices needing inter-
vention. It consists of:
1. Anonymised extraction of the data set required to report
whether there was any quality improvement. The usual com-
ponents are:
A. Denominator to allow standardisation of prevalence,
B. Subset of people with the target condition—to create a
virtual disease register,
C. Clinically relevant comorbidities, risk factors and
treatment.
2. Processing these data listed above to make them informative
to the target audience. In addition providing comparative feed-
back combined with academic detailing. A key feature is pre-
senting comparative feedback comparing practices at twice
yearly meetings held within a locality/primary care organisa-
tion. These meetings are called Data Quality Workshops
(DQW), generally locally led with a consultant of the relevant
discipline attending as a specialist resource.
3. In addition to the presentation at the DQW, practices are pro-
vided two additional printed aids:
A. ‘Laminate’—a single laminated A4 page summary of
the practice demographics and case ascertainment
compared with others who attended the DQW. This is
for the practice notice board or other prominent loca-
tion (we recommend wherever they take their breaks).
B. Workbook—a slide by slide explanation of the DQW
presentation—and what the data mean for their prac-
tice, compared with their peers and any evidence-based
guidance.
4. Running local searches in the practices to provide lists of
patients that need to be targeted for intervention. These lists
are usually generated by an individual GP. Experiential learning
is that audit lists of up to 150 per 10 000 registered patients
result in change.
5. Supporting education about the evidence base and providing
coding or other computerised medical record system training
is provided as required.
6. Participants have been encouraged to contribute to the future
development of the ABE programme.
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error, there were actually 29). This was carried out to
test whether QI might be secondary to improving conﬁ-
dence, knowledge and competence in managing CKD.17
We identiﬁed four practices, two from each active study
arm for in-depth process evaluation using focus groups.
Participants and recruitment
At the start, four general practices were selected to par-
ticipate in the process evaluation, in parallel to the ran-
domised control study. Two practices from this group
received ABE, and the other two G&P. These practices
participated in focus groups at the midpoint and at the
end of the trial period. We purposively selected one
from the north, one from the south, and one city and
one non-urban practice from each active study arm.
Another four practices were involved in a focus group at
the end of the project (again, two received ABE and the
other two G&P). The additional focus groups were
undertaken in order to increase the representativeness
of the ﬁndings (12 groups in total). All focus groups
were attended by the 6–9 members of the multiprofes-
sional team (general practitioner (GP), practice nurses,
healthcare assistants and practice manager). The focus
groups were undertaken by a member of the research
team and an experienced qualitative researcher.
Data collection
Focus groups are advantageous in their ability to extract
the attitudes and beliefs of participants, and are more
likely to do so when compared with individual interviews
or observation.18 19 The focus groups comprised 6–9
health professionals; GPs were a majority in all, and
other professions were practice manager and practice
nurse. A non-prescriptive interview guide was developed
by the research team in order to guide the interaction
and prompt reﬂection, but no attempt was made to
suggest responses or limit discussion, thus allowing
maximal interaction between participants and an oppor-
tunity for related concepts to emerge. The four areas
explored were:
1. Understanding the effects of the two QI
interventions;
2. Explore the extent to which practices were aware of
the interventions and their impact;
3. Understanding how CKD management had changed
since P4P was introduced;
4. Identifying any other factors which may have
impacted on the quality of CKD management during
the study.
Data analysis
Focus groups data were transcribed and analysed using a
multistep iterative process known as framework analysis.
The framework method was selected because it is a
method that is considered suitable for use in teams
where not all members have experience of qualitative
research.20 The framework approach consists of an
initial period of familiarisation with the data; verbatim
Table 1 Guidance introduction before and during the QICKD trial, including variation in BP target and proteinuria measures
Year Guidance Body Role BP
2005 National Service Framework for
renal disease: Part 2 Chronic
Kidney Disease
Department of
Health
National guidance on
managing CKD
Strict application of National
guidance for Hypertension
and/or Diabetes
2006 Royal College of Physicians and
Renal Association
Included other
Royal Colleges
Guidelines from joint
learned societies to fill a
gap in guidance
>140/90 mm Hg to an optimal
BP of <130/80 mm Hg
>130/80 mm Hg to an optimal
BP of <125/75 mm Hg where
the PCR ratio is >100 mg/mmol
2006 QOF CKD guidance NHS
Employers, then
NICE
P4P for chronic disease
management
<140/85—though people with
comorbidities also subject to
appropriate guidance (eg,
diabetes)
2007 Recruitment into QICKD trial*
2008 Early identification and
management of chronic kidney
disease in adults in primary and
secondary care
NICE Clinical Guideline No 73
(CG73), National
evidence-based guidance
Systolic BP >140 mm Hg
(target range
120–139 mm Hg) and the
diastolic BP below 90 mm Hg.
120–129/<80 in DM with CKD
where ACR >2.5 (men) >3.5
(women) or where ACR >70
2010 Final data collection QICKD trial*
ACR, albumin:creatinine ratio; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; NHS, National Health Service; NICE,
National Institute for Health and Care Excellence; P4P, pay-for-performance; PCR, protein:creatinine ratio; QICKD, Quality Improvement in
Chronic Kidney Disease; QOF, Quality and Outcomes Framework.
*Key dates provided about when practices were recruited into the QICKD trial and when it ended, compared to the dates relevant guidance
were published.
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transcripts were created by a specialist clerical ofﬁcer at
the University of Surrey, noting recurrent or intensely
expressed issues and themes.21 We subsequently devel-
oped a thematic framework using the issues and themes
noted in the ﬁrst stage and their relevance to the four
areas intended to be explored in the focus groups.
These themes were then indexed and charted according
to themes and subthemes. The ﬁnal step was a review of
these charted themes in order to identify associations,
detect anomalies and reﬁne the thematic framework.
Thus, a set of major themes is outlined in the Results
section, with associated subthemes.
Ethical considerations
The study, including its process evaluation, was approved
by a research ethics committee prior to the start of the
trial.
FINDINGS
Overview of the findings
Overall, the practitioners found that participating in the
trial improves their understanding of CKD. However, the
concept of CKD itself, how risk is stratiﬁed in CKD and
changes in management made it a challenging condi-
tion to explain to patients. Practitioners perceived that
P4P targets may have had a greater impact on CKD man-
agement than the study intervention. They enjoyed and
found the face-to-face education useful, but some found
the paper feedback they received confusing.
Improving the validity of the CKD disease register
Practitioners were positive about the concept of a CKD
disease register. Several participants acknowledged that
initially they were not aware that having two estimated
glomerular ﬁltration rate (eGFR) readings, at least
3 months apart, was needed to meet the diagnostic cri-
teria for CKD; creation of a CKD register was considered
useful in limiting overdiagnosis of CKD.
We used to put our patients on [the CKD disease regis-
ter] straight away if they only came once in for eGFR
measurement which was below 60, or it might be 58 and
they ended up going on the register…the register has
maybe got a bit smaller after that and the reason for that
was actually cleaning it up and making sure patients are
there appropriately. (FG2)
Nevertheless, there was variation between practices in
how the register was maintained and new patients added.
Some practices were systematic and used audit tools to
identify cases, while others opportunistically identiﬁed
patients with CKD in routine primary care consultations,
or looked for cases proactively, in chronic disease man-
agement clinics (eg, practice hypertension clinics).
Explanation of CKD diagnosis
Many practitioners commented on the difﬁcult balance
between avoiding unnecessary anxiety and social stigma
by giving patients what they considered a potentially
confusing diagnosis. They were concerned about label-
ling patients with a chronic disease label, especially
older people in whom CKD is extremely common. At
the same time, they did not want to conceal information
from them. It was noted that patients often required a
great deal of reassurance and explanation of the condi-
tion, even with early-stage disease—particularly given the
often silent nature of the condition:
But sometimes it’’s difﬁcult, especially with CKD 3 for
example you just kind of, you don’t want to label them as
chronic kidney disease and it’s difﬁcult for them to kind
of come to terms with it. (FG1)
People automatically think dialysis, don’t they? So ‘You’ve
got kidney disease’ and they’re like, ‘Oh, my god. (FG4)
Although some participants did acknowledge that pro-
viding the diagnosis of CKD is necessary for patient con-
cordance with treatment, most chose to use terms such
as ‘kidney strain’, as opposed to the words ‘chronic
kidney disease’, and discuss it as a function of age rather
than active disease. Since a CKD diagnosis was based on
laboratory results, often the diagnosis was added to a
patient’s records when results were reviewed rather than
in a face-to-face contact. It was often not practical with
the business of the day and the number of results to
inform all patients and to cross-check if there had been
a proteinuria test and if it were positive. Both of these
factors probably contribute to the observation that not
all patients with CKD were informed of their diagnosis.
Meeting CKD targets
A key issue raised was the contradictory BP targets
advised for patients with CKD in national guidance and
the P4P scheme. The BP guidance set out by the Royal
College of Physicians and Renal Association was different
from that set within the P4P indicators for primary care,
which were again different from that set by National
Institute for Health and Care Excellence (NICE), the
national body that develops evidence guidelines (table
1).22 23 While many practitioners chose to follow the P4P
BP target, others altered the aggressiveness of their man-
agement dependent on the patient group:
I tend to go for younger patients particularly. If they are
38 and they have got hypertension and we are treating
them, the QOF [P4P] target is 150/90 and if we are
getting 148/88, it’s okay but they have got another thirty
years of that. (FG1)
Guidance from NICE was felt to be too lengthy and
confusion was frequently reported with the interpret-
ation of the newly introduced proteinuria measure,
albumin:creatinine ratio (ACR), both in its measure-
ment and its effect on patient management:
I think the confusion is what level of ACR you act on.
I think it’s slightly clearer with the NICE guidelines,
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basically if you’re talking about ACRs of more than 30, 70
or 30 if they’ve got blood, and I think the little bit of
uncertainty is in diabetics an ACR of more than 3.5 is
classed as microalbuminuria but in non-diabetics what do
you do with ACRs between 3 and 30? I think that’s the
slight area of uncertainty that I feel. (FG6)
The impact of the study interventions
The question of what impact study interventions (ABE
and guidelines with prompts) had on clinical practice
drew mixed responses. Two of the four practices felt
guidelines were useful both to base their local policy on,
and more commonly as a reference for clariﬁcation:
It was shown very clear when to refer, when you’ve got
proteinuria when to refer, when, so that not everyone
with proteinuria had to be referred and so the guidelines
I thought were very clear and good. (FG1)
Practices responding in this fashion had generally
been proactive in seeking out and using local guidelines,
and implementing new policy such as ACR measure-
ment. They also commented on the usefulness of the
educational meetings, particularly where their represen-
tative could discuss concerns with a consultant nephrolo-
gist and subsequently drive change within their group.
However, the other two practices felt that the written
information provided, both in the form of audit data
and prompts, was not especially useful:
And there was a whole load of audit stuff that went in
that I just looked through, but again it was quite compli-
cated, involved I should say, involved, so I’m afraid we
didn’t take any notice of that either. (FG8)
A theme throughout all focus groups was the difﬁculty
in interpreting the effect of study interventions given
the P4P introduction in tandem, and the expected famil-
iarity that develops with new policy implementation over
time. While some noted that interventions provided
more background and understanding of the evidence
behind national guidelines (particularly soon after their
initial introduction), P4P targets remain the driving
force behind local practice:
So I think that’s universally accepted, that if you keep the
QOF [P4P] up-to-date you’ll get money, you’ll get points,
so I think you can’t beat on that one. (FG5)
Ideas for future clinical practice
Ideas for future practice were largely clustered around
tools to make the process of updating the CKD register
or accessing guidelines more efﬁcient, as well as to
improve access to specialist advice. A number of prac-
tices identiﬁed the scope for guidelines with prompts to
be incorporated into their current electronic patient
management systems:
I think one of the [ideas], is to develop some sort of soft-
ware which then integrates the clinical system so when
you see patients [with] CKD it actually pops up a window
saying you haven’t done x, y, z. (FG1)
Others noted that workshops or ‘virtual clinics’ where
practice members had direct access to specialists proved
very useful:
We had quite a useful exercise where we had, it wasn’t
actually for CKD but it could apply to CKD, we had a dia-
betic endocrinologist come and a diabetic specialist
nurse and they sat down and they did a virtual clinic
involving diabetics who had HbA1c under ten and they
said what to do about them. (FG2)
Summary
Five main themes emerged from this study (table 2).
First, the need to improve the accuracy and understand-
ing of the CKD disease register; most importantly, many
people were included who may not have had two qualify-
ing eGFR measurements at least 3 months apart.
Second, a diagnosis of CKD was hard for some profes-
sionals to share with patients, who they felt needed a lot
of reassurance. Some clinicians avoided using the term.
Third, practitioners were more driven to change practice
by P4P indicators than they were by evidence-based guid-
ance; they tended to use the former to drive their prac-
tice. Fourth, the study provided an opportunity to
develop practice guidance and the presence of a special-
ist nephrology doctor or nurse was useful, whereas much
of the study information was less so. Finally, participants
could see how prompts, role play through virtual clinics,
workshops and updates might be useful tools for
keeping up to date.
DISCUSSION
Principal findings
The process evaluation practices in the QICKD trial
were exposed to the intervention as planned; those
exposed to ABE had the chance to test some of their
uncertainties about CKD and its management. Reaction
towards the study interventions and P4P varied both
between and within individual practices. However, ﬁve
major themes consistently emerged in analysis of focus
group discussions. The introduction of a nationally
deﬁned CKD register was generally viewed as a positive
step in formalising diagnostic criteria, reducing ‘false
additions’ and facilitating audit. Practices were encour-
aging about the effects of study interventions, particu-
larly ABE, in improving awareness and understanding of
CKD, and would largely support similar interventions in
future. The ABE practices found the interaction with a
specialist advising about how to implement guidance
particularly useful. However, P4P measures were
regarded as the main driving force behind changes in
practice.
Concerns persist about the difﬁculty in explaining the
diagnosis of CKD to patients, the stratiﬁcation of risk
and the inconsistency in updating the CKD register.
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Additionally, many participants questioned the useful-
ness of conﬂicting BP guidelines from NICE and P4P,
which added to what was perceived to be unnecessary
complexity (table 1).
Practice implications
QI interventions such as ABE and G&P appear to have
some positive inﬂuence on the primary care manage-
ment of CKD. Practitioners reported that they found the
interactive sessions where their data were presented and
they could interact with a specialist nephrologist most
useful. Receiving information on paper was remembered
but perceived to be confusing. The costs of providing
such sessions are obviously high but could be used where
achieving change was a high priority and such sessions
could be integrated into other locality-based educational
interventions. In contrast, providing written information
did not appear to have an impact, and maybe those
looking to improve quality by mailing out to practices
should think carefully about whether this is likely to be
effective, especially where there is complexity.
However, over the period of this study, the major
impetus for improving quality appeared to be exposure
to P4P. Where QI interventions appear to be particularly
useful is in providing further guidance, in conjunction
with newly introduced P4P targets, and in clarifying
any inconsistencies or confusion. QI interventions can
support introduction of new guidelines by familiarising
practices with new evidence and offering support and
constructive feedback for implementation, which would
not otherwise be available. Interaction with a specialist, as
well as consulting about the level of care in the practice,
Table 2 Conceptual framework listing main themes and subthemes derived from the process evaluation
Main themes Subthemes derived from focus group analysis
A. Improving the validity of the
CKD register
A1. Stop diagnosing CKD on the basis of one low eGFR reading; instead, use two
3 months apart.
A2. Auditing is carried out opportunistically, etc.
A3. Introduction of a CKD disease register curbed diagnostic overenthusiasm.
A4. Clinical judgement exercised over whether patients with variable scores around the
threshold should be included on the register.
A5. If the GP feels a patient with CKD will not benefit from treatment they should still put
them on register but ‘exception report’ them (this is a process that makes them no
longer part of pay-for-performance indicator group).
A6. Nurses pick up patients with low eGFR through clinics run for the primary prevention
of heart disease, or through yearly audit/checks of computerised records.
B. Explaining to patients they
have CKD
B1. Tension between not hiding CKD diagnosis from patients and wishing to avoid
causing excessive anxiety and social consequences of labelling.
B2. Avoiding the phrase ‘chronic kidney disease’, using ‘kidney strain’ instead.
B3. Giving CKD diagnosis is necessary for patient participation in management.B4.
Patients require a lot of reassurance postdiagnosis.
C. Meeting CKD targets
(BP, ACR)
C1. Few problems in adopting ACR as routine practice.
C2. Unsure about necessity of early morning urine sample for ACR.
C3. Uncertainty about significance of ACR in patient management.
C4. Use pay-for-performance rather than evidence-based (NICE) BP maintenance
targets.
C5. Use evidence-based (NICE) rather pay-for-performance targets, as the lower the BP
level the better.
C6. Setting and maintaining BP targets are dependent on patient group.
C7. National evidence-based (NICE) guidelines too detailed to be practical.
C8. Increase in workload following CKD pay-for-performance indicator was unpopular.
D. Impact on practice of the study
interventions
D1. Base local practice on study guidelines.
D2. Presence of a nephrologist at workshops very useful.
D3. Difficult to determine whether study interventions are a catalyst for change or
introduction of pay-for-performance targets.
D4. Study’s information resources not useful.
D5. Developed own template for tests following participation.
E. Ideas for future practice E1. Electronic management guideline prompt, that is, desktop icon, flagged up through
pay-for-performance reminders (built into primary care computerised medical record
systems)—more practical than paper-based.
E2. Run ‘virtual clinical’ as training exercise.
E3. Electronic practice updates.
E4. Workshops to compare experience with other practices.
ACR, albumin:creatinine ratio; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NICE, National
Institute for Health and Care Excellence.
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as part of the ABE process, rather than about individual
patients, was a different but useful experience.
Greater appreciation of the beneﬁts of identifying
people with CKD and a fuller understanding of appro-
priate CKD management beyond the mechanistic appli-
cation of P4P indicators is needed. This evaluation
revealed inconsistency in application and gaps in clini-
cians’ understanding. These ﬁndings are also replicated
in other studies.24 Concurrent introduction of QI inter-
ventions with future P4P targets and national guidance
plus continuing education would avoid confusion over
their use and could increase speed of uptake and
achievement of targets. This study has shown that
primary care practitioners are generally supportive of
such measures and found them useful in guiding their
own practice’s adoption of guidelines. However, despite
this, practitioners reported difﬁculty in explaining a
diagnosis of CKD to their patients. There appears to be
a gap in current guidance, namely a lack of explanation
about how healthcare professionals could best communi-
cate the nuances of a condition such as a CKD diagnosis
to patients, a problem reported by other studies.25 26
Comparison with the literature
Much research has focused on the extent to which P4P
affects clinical practice in primary care, much less about
what constitutes effective QI, or what promotes effective
management of CKD in primary care. There is evidence
that P4P does indeed result in acceleration of target
achievement, such as a progressive reduction in BP8 or
improved diabetic control.27 However, this improvement
appears to slow once targets are reached, and quality of
care can decline for non-incentivised criteria.28 New P4P
guidelines are not always immediately accepted and
embraced by practices, and low practitioner conﬁdence
in management of CKD (particularly high-risk patients,
such as those with proteinuria) provides a plausible
explanation as to why they might have a negative effect
on target attainment, even where P4P is in place.17
There may be a gradual, underlying diffusion of knowl-
edge and management of CKD.29 There appeared a
greater acceptance among healthcare professionals of
CKD as a relevant diagnosis, compared with previous
studies,23 but this may simply be due to the length of
time that has now elapsed since the introduction of P4P
(2006) and NICE guidance (2008, table 1).
It has been shown that QI strategies can be useful in
improving speciﬁc targets in CKD, such as BP14 30 and
requirement for renal replacement therapy.31
Limitations
This study examined a small number of practices; we pur-
posively sampled two each from the two study intervention
arms and from different parts of the country. The practices
contained a larger number of individuals and it is possible
that opinion leaders within those practices, or practices
and localities within which they were based, may have
adopted procedures and processes that were not
representative of the study practices as a whole.
Additionally, these individuals may have unduly dominated
the focus group discussion, compared with more junior
practice members. These limitations are all possible, but
the study team which conducted these focus groups was
also exposed to the other practices involved in the trial.
Additionally, QI interventions such as ABE or G&P can
vary in design between studies, with no common detailed
approach for their implementation. In systems such as the
National Health Service (NHS), data are readily accessible,
and creating personalised feedback for practices should
be relatively straightforward and is already done in a
number of areas such as prescribing. However, meeting
time for practitioners is expensive, especially where in ABE
a facilitator (to explain the data) and a specialist physician
or nurse are brought along too. While these roles might
be combined, ABE is an expensive interaction, an issue
raised in a commentary on the QICKD trial.32
Further research
While there has undoubtedly been engagement with CKD
through the P4P process, the case for P4P in CKD remains
unproven.33 34 Future research should seek to determine
whether improvements identiﬁed following QI interven-
tions can be generalised. We need to have a greater under-
standing about why clinicians found this a difﬁcult
diagnosis to explain to patients. We also need to test
whether computerised medical record systems could
improve the way they display information; in the case of
CKD, a combination of ﬁnding two renal function tests at
least 3 months apart, whether there is a signiﬁcant level of
proteinuria, a relevant comorbidity, and if BP is correctly
controlled for this level of risk are all recorded in different
places (table 1). We also need to know whether ABE is cost-
effective. It is only likely to be so if embedded into existing
educational processes carried out on a locality basis.
CONCLUSIONS
P4P incentives were the major driver of improved manage-
ment of CKD in primary care (box 2); however, QI inter-
ventions can have a complementary role. This process
evaluation demonstrates the place for a QI intervention
alongside the introduction of P4P guidelines. The focus
groups reported positive interactions from ABE,
Box 2 Summary conclusions
▸ Chronic kidney disease (CKD) is a difficult condition to explain
to patients, risk stratification is complex, and the relevant data
are dispersed through computerised medical record systems.
▸ Pay-for-performance (P4P) incentives are the major driver for
change in the management of CKD in primary care.
▸ Quality improvement interventions may have a complementary
role with future P4P initiatives.
▸ Audit-based education was positively received by practices,
but further research is needed to demonstrate whether it is
cost-effective.
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particularly with a kidney doctor or nurse. It is plausible
that the interaction involved in ABE contributed towards
the modest but signiﬁcantly greater reduction in systolic
BP in this arm compared with sending out G&Ps.
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